

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.							Date	Name	Class	Subclass	Filing Date if Appropriate
PP	5	8	7	6	7	2	8	03/02/1999	Kass HD et al.			
PP	5	8	7	4	8	0	4	02/23/1999	Rogers SP			
PP	5	6	4	8	0	8	9	07/15/1997	Shawkat T			

FOREIGN PATENT DOCUMENT

PP	Document No.							Date	Country	Class	SubClass	Translator
	7	9	3	9	6	4						Yes No
								09/10/1999	Europe (EP)			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

Harvard School of Public Health Jan 2004, <http://www.researchmatters.harvard.edu/story.php?article_id=673>

Buckwold, Beer, Doris, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;

Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS , Wall Street Journal December 8, 2003 <<http://online.wsj.com/article/SB107083909136415400.html>>

Enfuvirtide (Fuzeon) for HIV Infection Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;

El-Awady, et al., Chem. Clinical Acta, 283(1-2):1-14 (1999)

McHutchison et al Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment fro Chronic Hepatitis C, New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner

Date Considered

4/14/04

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103


Serial No.
09/955,877

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Yokozawa, et al., J. Traditional Medicine, 15(4):202-207 (1998);

Alter, M.J., Hepatology, 26(1):625-655 (1997);

Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);

D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);

Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);

D.C. Dale and D.D. Federman, eds. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);

Hipps, et al., Infect. Dis. 168:789-790 (1993);

Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);

Fields, Virology 2nd ed, New York, Raven Press, 1990 p691;

Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);

Medicinal Plants of North Africa, pp. 74-75 (1983);

Bergmeyer and Horder, Clin. Chen. Acta 105147 f. (1980);

Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, p.169 (1980);

International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Biochem., 18:521-534 (1980);

no copies

NY02:472768.1

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Bergmeyer H-U. Principles of Enzymatic Analysis. Verlag Chemic, (1978);

Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970);

Linus Pauling, General Chemistry, New York, Raven Press 1970, p 744

No Copies

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.